Stockscreener 앱 받기
43.90
0.50%
0.22
시간 외 거래:
43.90
전일 마감가:
$43.68
열려 있는:
$43.76
하루 거래량:
840.68K
Relative Volume:
0.44
시가총액:
$4.67B
수익:
$761.41M
순이익/손실:
$98.16M
주가수익비율:
53.66
EPS:
0.8181
순현금흐름:
$141.79M
1주 성능:
+4.85%
1개월 성능:
+36.55%
6개월 성능:
-42.85%
1년 성능:
-36.92%
1일 변동 폭
$43.27
$44.42
1주일 범위
$41.00
$44.42
52주 변동 폭
$28.66
$91.00
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
43.90 | 4.65B | 761.41M | 98.16M | 141.79M | 0.8181 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
CORT FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics ... - Caledonian Record
Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept - GlobeNewswire
CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - GlobeNewswire Inc.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Pomerantz LLP Shares Class Action Details With Shareholders in Corcept Therapeutics Incorporated – CORT - ACCESS Newswire
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - The Malaysian Reserve
Press releases provided by CNW - Techaeris
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK - MSN
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - PR Newswire
Corcept Leaders Sued Over Drug-Approval Remarks, Stock Sales - Bloomberg Law News
Bragar Eagel & Squire, P.C. Reminds Investors that a Class - GlobeNewswire
Corcept Therapeutics Incorporated Sued for Securities Law - GlobeNewswire
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
Corcept's Lifyorli Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer - National Today
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates - Yahoo Finance
Corcept’s Lifyorli shows 35% reduction in death risk for ovarian cancer - Investing.com Australia
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - NewMediaWire
FinancialContentDEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - FinancialContent
Corcept Therapeutics (CORT) Unveils Promising Survival Data from ROSELLA Trial - GuruFocus
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds - Yahoo Finance
INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit ... - Bluefield Daily Telegraph
CORT Shareholder Alert: Corcept Therapeutics Incorporated - GlobeNewswire
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Contact Kaplan Fox Before April 21, 2026 - FinancialContent
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Corcept Therapeutics (CORT) - The Globe and Mail
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
CORT DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT Investors Have Opportunity to Lead Corcept - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
Corcept therapeutics officer Guyer sells $819k in shares By Investing.com - Investing.com UK
Corcept (NASDAQ: CORT) CDO sells 20,000 shares after option exercise - Stock Titan
Corcept (CORT) director Wilson reports 5,000-share stock gift via trust - Stock Titan
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Inve - The National Law Review
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026 - FinancialContent
Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation - ChartMill
Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Corcept (CORT) Class Action Alleges Misstatements on FDA Data ConcernsHagens Berman - ChartMill
Insider sells 20,000 CORT shares after option exercise (CORT) - Stock Titan
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):